The Role of Glycocalyx Integrity in the Primary Prevention of Major Cardiovascular Events
Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6 Year Follow up Study
University of Athens
500 participants
Jan 10, 2013
OBSERVATIONAL
Conditions
Summary
The researchers intend to recruit individuals who are referred for a routine screening in the primary prevention outpatient clinic of Attikon University hospital, Athens According to institutional protocols, a detailed medical history for atherosclerotic risk factors and current medication is recorded and a baseline clinical examination is performed. Moreover fasting blood samples are drawn to diagnose the presence of diabetes mellitus and hyperlipidemia. Glycocalyx examination is performed at the same visit. The subjects are revaluated at one month and then followed up according to the attending physician's instructions. Pulse wave velocity and the rest pulse wave analysis parameters were also calculated to determine the additive predictive value for cardiovascular events beyond SCORE2. All subjects are followed up for adverse events (death, stroke, myocardial infarction, hospitalization for heart failure) for 6 years after enrollment via telephonic contact and planned appointment at the outpatient clinic.
Eligibility
Inclusion Criteria1
- We recruit individuals who were referred for a routine screening in the primary prevention outpatient clinic of Attikon University hospital.
Exclusion Criteria8
- History of Coronary artery disease,
- History of Peripheral Arterial Disease,
- History of Heart failure
- History of Stroke
- hepatic failure
- renal failure,
- active neoplasia
- poorly controlled DM, defined as Hba1C>7%
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Measurement of Perfused Boundary Region of sublingual microvessels to assess thickness of endothelial glycocalyx Measurement of Pulse Wave Velocity to quantify arterial stiffness
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04646252